Replimune Group (NASDAQ:REPL) Price Target Raised to $27.00

Replimune Group (NASDAQ:REPL) had its target price upped by BMO Capital Markets from $18.00 to $27.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts have also recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright increased their target price on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Jefferies Financial Group raised their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.14.

Replimune Group Price Performance

Replimune Group stock opened at $13.59 on Wednesday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The business’s 50 day simple moving average is $12.28 and its 200 day simple moving average is $11.33. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a market cap of $929.83 million, a price-to-earnings ratio of -4.46 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Sell-side analysts forecast that Replimune Group will post -2.88 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently modified their holdings of REPL. Point72 DIFC Ltd bought a new position in Replimune Group during the second quarter valued at approximately $57,000. Erste Asset Management GmbH bought a new position in shares of Replimune Group during the 3rd quarter valued at $133,000. China Universal Asset Management Co. Ltd. raised its position in Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares during the period. BNP Paribas Financial Markets raised its position in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after purchasing an additional 6,748 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Replimune Group in the third quarter worth $222,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.